Crossject - Termination of coverage
Edison Investment Research is terminating coverage on Crossject (ALCJ). Please note you should no longer rely on any previous research or estimates...
75 Views
Crossject - On track for filings next year
Crossject recently reported FY17 results and that it remains on track for regulatory filings for several programmes in 2019, including Zeneo...
80 Views
Adding asthma
Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, Zeneo, across a variety of...
85 Views
A reinforced cash position
Crossject recently announced that it has received regulatory approval to launch the bioequivalence study for Zeneo Midazolam (being developed for...
153 Views
Timeline adjustments
As part of its revised strategic plan, Crossject has expanded its partnership with CENEXI to fill and finish all of Crossject’s products in all...
56 Views
No more insights